Argenx

Developer of antibody-based drugs to treat autoimmune diseases and cancer

placeGhent, Flanders, Belgium calendar_todayFounded 2008 groups355 employees language argenx.com

Registered entities

Social engagement

Social engagement: 122.8K social following, 10 posts in the last 12 months — below the industry typical range.

Investor mix

22 investors on record; lead investors include Omnes Capital, VIB, PMV, Forbion; 3 have since exited.

Investor typeCountShare
Venture capital1150%
Private equity627%
Bank & private debt15%
Other / undisclosed418%

Hiring activity

Hires occasionally

3 roles tracked across 2 of the last 12 months

11 Dec 2025 · Senior Scientist Computational Chemistry · Ghent

31 Oct 2025 · Director of Corporate Strategy · Ghent

3 Sep 2025 · Director of Discovery & Early Research Strategy · Ghent

11 Feb 2025 · Senior Scientist CMC · Ghent

22 May 2024 · Product Quality Manager · Ghent

Based on job postings tracked across public sources.

Recent activity

26 Jun 2026
Event
International Congress on Neuromuscular Diseases
23 Jun 2026
Product launch
Patient Engagement and Capability Accelerator (PECA)
16 Jun 2026
Event
BIO International 2026
Coming soon